Skip to content

Evaluation of CTA on the Assessment of Brain Death

Evaluation of CTA on the Assessment of Brain Death

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04914039
Enrollment
63
Registered
2021-06-04
Start date
2021-02-01
Completion date
2023-02-01
Last updated
2021-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Death

Keywords

brain death, CT angiography

Brief summary

At present, different countries have different standards for the diagnosis of brain death, but according to the classic brain death confirmation test, it needs to be combined with transcranial Doppler, EEG, evoked potential and apnea test in clinical practice. Some patients cannot undergo a complete clinical examination and apnea test due to certain factors, and the determination of brain death is limited. The American Academy of Neurology (AAN) guidelines regard cerebral angiography as an acceptable auxiliary examination and is widely regarded as the gold standard for cerebral blood flow evaluation. CT cerebrovascular angiography (CTA) is a noninvasive and widely used examination method that can identify missing or severely reduced cerebral blood flow. However, due to limited experience and lack of sufficient evidence to prove its reliability, it is not included in the AAN A recognized auxiliary examination; there are also a large number of domestic and foreign literature reports that CTA can be used as a new confirmation test for clinical judgment of brain death. This study aims to explore the value of CTA in the judgment of patients with brain death.

Interventions

COMBINATION_PRODUCTCombination Product

Cases of brain death confirmed by the classic brain death confirmation test

OTHERNO CTA examination

NO CTA examination

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
12 Years to 72 Years
Healthy volunteers
No

Inclusion criteria

* Recruiting, no definite

Exclusion criteria

* Recruiting, no definite

Design outcomes

Primary

MeasureTime frameDescription
CTA used as an auxiliary diagnosis to determine brain deaththrough study completion, an average of 3 years.CTA used as an auxiliary diagnosis to determine brain death

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026